[{"orgOrder":0,"company":"Veru","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Enobosarm","moa":"Selective androgen receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Veru","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Veru \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Veru \/ Not Applicable"},{"orgOrder":0,"company":"University of Adelaide","sponsor":"Veru","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Enobosarm","moa":"Androgen receptor","graph1":"Oncology","graph2":"Phase II","graph3":"University of Adelaide","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"University of Adelaide \/ Veru","highestDevelopmentStatusID":"8","companyTruncated":"University of Adelaide \/ Veru"},{"orgOrder":0,"company":"Veru","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Enobosarm","moa":"Selective androgen receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Veru","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Veru \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Veru \/ Not Applicable"},{"orgOrder":0,"company":"Veru","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Collaboration","leadProduct":"Abemaciclib","moa":"CDK4","graph1":"Oncology","graph2":"Phase III","graph3":"Veru","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Veru \/ Eli Lilly","highestDevelopmentStatusID":"10","companyTruncated":"Veru \/ Eli Lilly"},{"orgOrder":0,"company":"Veru","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Enobosarm","moa":"Selective androgen receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Veru","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Veru \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Veru \/ Not Applicable"},{"orgOrder":0,"company":"Veru","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Abemaciclib","moa":"CDK4","graph1":"Oncology","graph2":"Phase III","graph3":"Veru","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Veru \/ Eli Lilly","highestDevelopmentStatusID":"10","companyTruncated":"Veru \/ Eli Lilly"},{"orgOrder":0,"company":"University of Tennessee Health Science Center","sponsor":"U.S. Department of Defense","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Funding","leadProduct":"Enobosarm","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"University of Tennessee Health Science Center","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"University of Tennessee Health Science Center \/ U.S. Department of Defense","highestDevelopmentStatusID":"10","companyTruncated":"University of Tennessee Health Science Center \/ U.S. Department of Defense"},{"orgOrder":0,"company":"Veru","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Enobosarm","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Veru","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Veru \/ Eli Lilly","highestDevelopmentStatusID":"10","companyTruncated":"Veru \/ Eli Lilly"},{"orgOrder":0,"company":"Veru","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Enobosarm","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Veru","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"","sponsorNew":"Veru \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Veru \/ Not Applicable"},{"orgOrder":0,"company":"Veru","sponsor":"Raymond James & Associates","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Public Offering","leadProduct":"Enobosarm","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Veru","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Veru \/ Raymond James & Associates","highestDevelopmentStatusID":"8","companyTruncated":"Veru \/ Raymond James & Associates"},{"orgOrder":0,"company":"Veru","sponsor":"Raymond James & Associates","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Public Offering","leadProduct":"Enobosarm","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Veru","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Veru \/ Raymond James & Associates","highestDevelopmentStatusID":"8","companyTruncated":"Veru \/ Raymond James & Associates"},{"orgOrder":0,"company":"Veru","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Enobosarm","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Veru","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"","sponsorNew":"Veru \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Veru \/ Not Applicable"},{"orgOrder":0,"company":"Veru","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Enobosarm","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Veru","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Veru \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Veru \/ Not Applicable"},{"orgOrder":0,"company":"Veru","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Enobosarm","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Veru","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Veru \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Veru \/ Not Applicable"},{"orgOrder":0,"company":"Veru","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Enobosarm","moa":"||Androgen receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Veru","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Veru \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Veru \/ Inapplicable"}]